| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.9 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.9 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |